COMMUNIQUÉS West-GlobeNewswire

SAFE SIGNS A STRATEGIC DISTRIBUTION AGREEMENT IN SPAIN WITH VORTROM BIOLOGICS
17/12/2025
SAFE SIGNS A STRATEGIC DISTRIBUTION AGREEMENT IN SPAIN WITH VORTROM BIOLOGICS A major partnership to accelerate Safe's development in the Spanish market Fleurieux-sur-l’Arbresle – France – December 17, 2025 – 8am - Safe [...]
SAFE ANNONCE LA SIGNATURE D'UN CONTRAT DE DISTRIBUTION STRATEGIQUE EN ESPAGNE AVEC VORTROM BIOLOGICS
17/12/2025
SAFE ANNONCE LA SIGNATURE D'UN CONTRAT DE DISTRIBUTION STRATEGIQUE EN ESPAGNE AVEC VORTROM BIOLOGICS Un partenariat majeur pour accélérer le développement de Safe sur le marché espagnol Fleurieux-sur-l’Arbresle – France [...]
Press release: Availability of the Q4 2025 Aide memoire
17/12/2025
Availability of the Q4 2025 Aide memoire Paris, France – December 17, 2025 . Sanofi announced today that its Q4 2025 Aide memoire is available on the "Investors" page of the company's website: Fourth quarter & full [...]
Communiqué de presse : Mise en ligne du document «Q4 2025 Aide mémoire »
17/12/2025
Mise en ligne du document «Q4 2025 Aide mémoire » Paris, France, le 17 décembre 2025 . Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « Q4 2025 Aide [...]
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands
17/12/2025
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands First Genio implants successfully performed at OLVG West and Zuyderland hospitals Mont-Saint-Guibert, Belgium – December 17, 2025, 7: [...]
Nyxoah Annonce le Lancement Commercial de la Thérapie Innovante Genio® Aux Pays-Bas
17/12/2025
Nyxoah Annonce le Lancement Commercial de la Thérapie Innovante Genio® Aux Pays-Bas Premières implantations Genio réalisées avec succès dans les hôpitaux OLVG West et Zuyderland Mont-Saint-Guibert, Belgique – 17 [...]
Press Release: Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema
17/12/2025
Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema Additional orphan designation reinforces Sanofi’s commitment to developing treatments for rare diseases [...]
Communiqué de presse : L’efdoralprine alfa de Sanofi obtient la désignation de médicament orphelin dans l’UE pour l’emphysème lié au déficit en alpha-1-antitrypsine
17/12/2025
L’efdoralprine alfa de Sanofi obtient la désignation de médicament orphelin dans l’UE pour l’emphysème lié au déficit en alpha-1-antitrypsine Une désignation de médicament orphelin supplémentaire renforce l’engagement [...]
Vireo Growth Inc. Enters into Definitive Agreement to Acquire Certain Assets of PharmaCann Inc.
17/12/2025
Acquired assets further optimize Vireo’s operating footprint in Colorado with addition of 17 dispensaries Transaction expands Vireo’s leadership position in the Colorado retail market with 41 total dispensaries Parties [...]
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
17/12/2025
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing [...]
HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors
17/12/2025
— First-in-human trial of candidate from the next-generation ATTC platform — — Simultaneous China and global clinical development strategy to expedite development process — HONG KONG and SHANGHAI and FLORHAM PARK, N.J [...]
Medline Announces Pricing of Upsized Initial Public Offering
17/12/2025
NORTHFIELD, Ill., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) announced today the pricing of its upsized initial public offering of 216,034,482 shares of its Class A common stock, at a public offering [...]
Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
16/12/2025
BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (the “Company” or “Galecto”) (Nasdaq: GLTO) today announced that the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 312 [...]
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services
16/12/2025
CHARLESTOWN, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac [...]
Health Care Advocates Slam Ford Government for Privatizing Surgeries While Pushing Public Hospitals into Deficit
16/12/2025
“A gross misuse of public funds” the Coalition warns as mass protests are planned TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Ontario’s public hospitals have been pushed into deficit and ordered to find cuts while the [...]
MAIA Biotechnology Announces $1.51 Million Private Placement
16/12/2025
CHICAGO, IL, Dec. 16, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today [...]
FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
16/12/2025
HOUSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the [...]
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
16/12/2025
Châtillon, France, December 16, 2025 DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years VITESSE met its primary endpoint: [...]
DBV Technologies annonce des résultats préliminaires positifs dans l’étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques à l’arachide
16/12/2025
Châtillon, France, le 16 décembre 2025 DBV Technologies annonce des résultats préliminaires positifs dans l’étude de phase 3 VITESSE sur le patch VIASKIN ® Peanut chez les enfants âgés de 4 à 7 ans allergiques à l’ [...]

Pages